

INSTITUTIONAL ETHICS COMMITTEE

Date: 29.09.2020

The request for giving information of study in website is discussed in the institutional ethics committee. The following information is approved to be published in the web site.

Study details:


Protocol title: A Randomised, Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) with MabThera® in Subjects with Previously Untreated, Stage II-IV, Cluster of Differentiation (CD)20-Positive, Low Tumour Burden Follicular Lymphoma.

Text content:

Low Tumour Burden Follicular Lymphoma: Aster Medcity, Aster Center for Clinical Research is a participating centre for a Government approved Phase III trial in patients with Previously Untreated, Stage II-IV, Cluster of Differentiation (CD)20-Positive, Low Tumour Burden Follicular Lymphoma After the initial screening patients who are eligible to participate in the study will be treated with an oral anti-cancer drug. For more details about the study please visit.

<http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=33639&EncHid=&userName=Follicular%20Lymphoma>. You can also contact _9895311888/9495805590 at Aster Medcity for booking an appointment."




Dr. Vijayamohan S - Member Secretary
Institutional Research and Ethics Committee
Aster Medcity, Kochi.